EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Teppei Yamada(Harvard University), Tetsuro Sasada(Kanagawa Prefectural Hospital Organization), Yuri Kasama-Kawaguchi(Kurume University), Emi Muta(Kurume University), Koichi Azuma(Kyushu University Hospital), Tomoaki Hoshino(Kurume University), Satoko Matsueda(Kurume University), Shunichi Sugawara(Sendai Kousei Hospital), Jintaek Kim(Dana-Farber Cancer Institute), Kyogo Itoh(Kurume University), Guang Lan Zhang(Boston University), Yuichi Yamashita(Fukuoka University Hospital), Takuto Yamashita(Kurume University), Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 23
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670